• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人类肿瘤抗原、免疫监视与癌症疫苗。

Human tumor antigens, immunosurveillance, and cancer vaccines.

作者信息

Finn Olivera J

机构信息

Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261, USA.

出版信息

Immunol Res. 2006;36(1-3):73-82. doi: 10.1385/IR:36:1:73.

DOI:10.1385/IR:36:1:73
PMID:17337768
Abstract

Cancer is a serious health problem as well as a scientific challenge. A lot has been learned about the process of transformation of a normal cell into a tumor cell by studying genes and proteins that regulate this process either in cis or in trans. However, whether these molecular mechanisms succeed in fulfilling their potential to give a clinically evident disease depends in great measure on the host response to those molecular changes. The work of my laboratory aims to provide evidence in animal models as well as in cancer patients that immune system can control cancer growth and that this important function can be improved through vaccination with well-defined tumor antigens.

摘要

癌症既是一个严重的健康问题,也是一项科学挑战。通过研究顺式或反式调节这一过程的基因和蛋白质,我们对正常细胞转变为肿瘤细胞的过程已经有了很多了解。然而,这些分子机制是否能够成功发挥其潜力,导致临床上明显的疾病,在很大程度上取决于宿主对这些分子变化的反应。我实验室的工作旨在在动物模型以及癌症患者中提供证据,证明免疫系统可以控制癌症生长,并且通过用明确的肿瘤抗原进行疫苗接种可以改善这一重要功能。

相似文献

1
Human tumor antigens, immunosurveillance, and cancer vaccines.人类肿瘤抗原、免疫监视与癌症疫苗。
Immunol Res. 2006;36(1-3):73-82. doi: 10.1385/IR:36:1:73.
2
[Features of functional activity of dendritic cells in tumor growth].[肿瘤生长中树突状细胞功能活性的特征]
Vopr Onkol. 2015;61(4):556-62.
3
The dawn of vaccines for cancer prevention.癌症预防疫苗的曙光。
Nat Rev Immunol. 2018 Mar;18(3):183-194. doi: 10.1038/nri.2017.140. Epub 2017 Dec 27.
4
Promises and limitations of murine models in the development of anticancer T-cell vaccines.小鼠模型在抗癌T细胞疫苗研发中的前景与局限
Int Rev Immunol. 2006 Sep-Dec;25(5-6):269-95. doi: 10.1080/08830180600992407.
5
Cancer vaccines.癌症疫苗。
Philos Trans R Soc Lond B Biol Sci. 2011 Oct 12;366(1579):2823-6. doi: 10.1098/rstb.2011.0101.
6
Progress in vaccination against cancer (PIVAC) 2002.2002年癌症疫苗接种进展(PIVAC)
Expert Rev Vaccines. 2002 Oct;1(3):261-3. doi: 10.1586/14760584.1.3.261.
7
Cancer vaccines: between the idea and the reality.癌症疫苗:理想与现实之间
Nat Rev Immunol. 2003 Aug;3(8):630-41. doi: 10.1038/nri1150.
8
[Oncoimmunology: some fundamental problems of cancer immunotherapy].[肿瘤免疫:癌症免疫治疗的一些基本问题]
Mol Biol (Mosk). 2007 Mar-Apr;41(2):355-68.
9
Therapeutic vaccination with tumor cells that engage CD137.使用激活CD137的肿瘤细胞进行治疗性疫苗接种。
J Mol Med (Berl). 2003 Feb;81(2):71-86. doi: 10.1007/s00109-002-0413-8. Epub 2003 Feb 8.
10
Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy.肿瘤特异性抗原和免疫佐剂在癌症免疫治疗中的应用。
Cancer J. 2011 Sep-Oct;17(5):325-30. doi: 10.1097/PPO.0b013e3182326004.

引用本文的文献

1
Endocrine Adverse Events in Patients Treated with Immune Checkpoint Inhibitors: A Comprehensive Analysis.接受免疫检查点抑制剂治疗患者的内分泌不良事件:一项综合分析。
Medicina (Kaunas). 2025 Jan 14;61(1):123. doi: 10.3390/medicina61010123.
2
Combination of pioglitazone and dendritic cell to optimize efficacy of immune cell therapy in CT26 tumor models.吡格列酮与树突状细胞联合应用以优化CT26肿瘤模型中免疫细胞治疗的疗效。
Bioimpacts. 2023;13(4):333-346. doi: 10.34172/bi.2022.24209. Epub 2022 Aug 9.
3
Pan-Cancer Survey of Tumor Mass Dormancy and Underlying Mutational Processes.

本文引用的文献

1
Evaluation of anticyclin B1 serum antibody as a diagnostic and prognostic biomarker for lung cancer.评估抗细胞周期蛋白B1血清抗体作为肺癌诊断和预后生物标志物的价值。
Ann N Y Acad Sci. 2005 Dec;1062:29-40. doi: 10.1196/annals.1358.005.
2
Tumor antigens and tumor antigen discovery.肿瘤抗原与肿瘤抗原的发现
Cancer Treat Res. 2005;123:89-111. doi: 10.1007/0-387-27545-2_4.
3
Immune response as a biomarker for cancer detection and a lot more.免疫反应作为癌症检测及更多用途的生物标志物。
肿瘤肿块休眠及潜在突变过程的泛癌研究
Front Cell Dev Biol. 2021 Jul 9;9:698659. doi: 10.3389/fcell.2021.698659. eCollection 2021.
4
Assessment of tumor-associated immune cells in laryngeal squamous cell carcinoma.评估喉鳞状细胞癌中的肿瘤相关免疫细胞。
J Cancer Res Clin Oncol. 2019 Jul;145(7):1761-1772. doi: 10.1007/s00432-019-02936-w. Epub 2019 May 21.
5
Skewed T-helper (Th)1/2- and Th17/T regulatory‑cell balances in patients with renal cell carcinoma.肾细胞癌患者中T辅助细胞(Th)1/2以及Th17/调节性T细胞平衡的倾斜
Mol Med Rep. 2015 Feb;11(2):947-53. doi: 10.3892/mmr.2014.2778. Epub 2014 Oct 27.
6
A cellular automaton model for tumor dormancy: emergence of a proliferative switch.一种用于肿瘤休眠的细胞自动机模型:增殖开关的出现。
PLoS One. 2014 Oct 16;9(10):e109934. doi: 10.1371/journal.pone.0109934. eCollection 2014.
7
Tumor immunotherapy using adenovirus vaccines in combination with intratumoral doses of CpG ODN.肿瘤免疫治疗采用腺病毒疫苗联合肿瘤内给予 CpG ODN。
Cancer Immunol Immunother. 2011 Sep;60(9):1309-17. doi: 10.1007/s00262-011-1038-y. Epub 2011 May 28.
8
Tumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the art.肿瘤免疫原性和对癌症疫苗治疗的反应性:最新进展。
Semin Immunol. 2010 Jun;22(3):105-12. doi: 10.1016/j.smim.2010.02.001. Epub 2010 Mar 11.
9
Dormancy of metastatic melanoma.转移性黑色素瘤的休眠
Pigment Cell Melanoma Res. 2010 Feb;23(1):41-56. doi: 10.1111/j.1755-148X.2009.00647.x. Epub 2009 Oct 19.
10
Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia.内源性肿瘤相关调节性T细胞的耗竭可提高过继性细胞毒性T细胞免疫疗法对小鼠急性髓系白血病的疗效。
Blood. 2009 Oct 29;114(18):3793-802. doi: 10.1182/blood-2009-03-208181. Epub 2009 Sep 1.
N Engl J Med. 2005 Sep 22;353(12):1288-90. doi: 10.1056/NEJMe058157.
4
Human tumor antigen MUC1 is chemotactic for immature dendritic cells and elicits maturation but does not promote Th1 type immunity.人类肿瘤抗原MUC1对未成熟树突状细胞具有趋化作用并引发其成熟,但不促进Th1型免疫。
J Immunol. 2005 Aug 1;175(3):1628-35. doi: 10.4049/jimmunol.175.3.1628.
5
Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer.与肿瘤相关抗原MUC1抗体相关的情况及其与卵巢癌风险的关系。
Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1125-31. doi: 10.1158/1055-9965.EPI-05-0035.
6
T cell-dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease.癌症和癌前疾病患者针对异常表达的细胞周期蛋白B1蛋白的T细胞依赖性抗体反应。
Clin Cancer Res. 2005 Feb 15;11(4):1521-6. doi: 10.1158/1078-0432.CCR-04-0538.
7
Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer.在接受手术切除和局部晚期胰腺癌患者中开展的、使用不同剂量MUC1肽与SB - AS2佐剂组成的MUC1疫苗的I期研究。
Cancer Immunol Immunother. 2005 Mar;54(3):254-64. doi: 10.1007/s00262-004-0581-1. Epub 2004 Sep 14.
8
MUC1 immunobiology: from discovery to clinical applications.MUC1免疫生物学:从发现到临床应用
Adv Immunol. 2004;82:249-93. doi: 10.1016/S0065-2776(04)82006-6.
9
Premalignant lesions as targets for cancer vaccines.癌前病变作为癌症疫苗的靶点。
J Exp Med. 2003 Dec 1;198(11):1623-6. doi: 10.1084/jem.20031787. Epub 2003 Nov 24.
10
Cancer vaccines: between the idea and the reality.癌症疫苗:理想与现实之间
Nat Rev Immunol. 2003 Aug;3(8):630-41. doi: 10.1038/nri1150.